{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:48Z","timestamp":1790915028478,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008052","name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10557-021-07257-0","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:03:21Z","timestamp":1631858601000},"page":"1187-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection"],"prefix":"10.1007","volume":"36","author":[{"given":"Juan Antonio","family":"Requena-Ib\u00e1\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Santos-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderly","family":"Rodriguez-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Urooj","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-8771","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"issue":"6","key":"7257_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0235-1","volume":"51","author":"JW Lee","year":"2019","unstructured":"Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med. 2019;51(6):1\u201313.","journal-title":"Exp Mol Med"},{"issue":"2","key":"7257_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","volume":"27","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27(2):281\u201398.","journal-title":"Cell Metab"},{"issue":"1","key":"7257_CR3","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.","journal-title":"PLoS One"},{"issue":"5","key":"7257_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","volume":"123","author":"NJ Kassebaum","year":"2014","unstructured":"Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615\u201324.","journal-title":"Blood"},{"issue":"5","key":"7257_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/1744-9987.12712","volume":"22","author":"T Akizawa","year":"2018","unstructured":"Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J. Burden of anemia in chronic kidney disease patients in Japan: a literature review. Ther Apher Dial. 2018;22(5):444\u201356.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"7257_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187\u201399.","journal-title":"Am J Nephrol"},{"issue":"10","key":"7257_CR7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631\u20134.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"7257_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000328037","volume":"32","author":"MI Yilmaz","year":"2011","unstructured":"Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: The name is self-explanatory. Blood Purif. 2011;32(3):220\u20135.","journal-title":"Blood Purif"},{"issue":"3","key":"7257_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.23876\/j.krcp.2017.36.3.209","volume":"36","author":"P Biggar","year":"2017","unstructured":"Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract. 2017;36(3):209\u201323.","journal-title":"Kidney Res Clin Pract"},{"issue":"20","key":"7257_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"7257_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791\u20138.","journal-title":"Kidney Int"},{"issue":"21","key":"7257_CR12","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"7257_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2362.2005.01528.x","volume":"35","author":"IC Macdougall","year":"2005","unstructured":"Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest. 2005;35(Suppl 3):32\u20135.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"7257_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000504850","volume":"6","author":"ZL Li","year":"2020","unstructured":"Li ZL, Tu Y, Liu BC. Treatment of renal anemia with roxadustat: Advantages and achievement. Kidney Dis (Basel). 2020;6(2):65\u201373.","journal-title":"Kidney Dis (Basel)"},{"issue":"5","key":"7257_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115\u201322.","journal-title":"Kidney Int"},{"key":"7257_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fmed.2020.00393","volume":"7","author":"Z Yan","year":"2020","unstructured":"Yan Z, Xu G. A Novel choice to correct inflammation-induced anemia in CKD: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat. Front Med (Lausanne). 2020;7:393.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"7257_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"7257_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jacbts.2020.05.006","volume":"5","author":"M Packer","year":"2020","unstructured":"Packer M. Mutual antagonism of hypoxia-inducible factor isoforms in cardiac, vascular, and renal disorders. JACC Basic Transl Sci. 2020;5(9):961\u20138.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"7257_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"7257_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1681\/ASN.2020010010","volume":"31","author":"M Packer","year":"2020","unstructured":"Packer M. Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: Implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors. J Am Soc Nephrol. 2020;31(5):907\u201319.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"7257_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1101\/gad.12.2.149","volume":"12","author":"NV Iyer","year":"1998","unstructured":"Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12(2):149\u201362.","journal-title":"Genes Dev"},{"issue":"12","key":"7257_CR22","first-page":"5447","volume":"12","author":"GL Semenza","year":"1992","unstructured":"Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447\u201354.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"7257_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"JW Kim","year":"2006","unstructured":"Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177\u201385.","journal-title":"Cell Metab"},{"issue":"5","key":"7257_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10059-010-0067-2","volume":"29","author":"A Loboda","year":"2010","unstructured":"Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors\u2014Similar but not identical. Mol Cells. 2010;29(5):435\u201342.","journal-title":"Mol Cells"},{"issue":"1","key":"7257_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yjmcc.2006.04.009","volume":"41","author":"C Willam","year":"2006","unstructured":"Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41(1):68\u201377.","journal-title":"J Mol Cell Cardiol"},{"issue":"24","key":"7257_CR26","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","volume":"23","author":"CJ Hu","year":"2003","unstructured":"Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23(24):9361\u201374.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"7257_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.yexcr.2012.02.035","volume":"318","author":"T Tanaka","year":"2012","unstructured":"Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012;318(9):1068\u201373.","journal-title":"Exp Cell Res"},{"key":"7257_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fnins.2019.00575","volume":"13","author":"R Ingrassia","year":"2019","unstructured":"Ingrassia R, Garavaglia B, Memo M. DMT1 Expression and iron levels at the crossroads between aging and neurodegeneration. Front Neurosci. 2019;13:575.","journal-title":"Front Neurosci"},{"issue":"5","key":"7257_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1101\/gad.1399906","volume":"20","author":"KL Covello","year":"2006","unstructured":"Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, et al. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20(5):557\u201370.","journal-title":"Genes Dev"},{"issue":"9","key":"7257_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","volume":"37","author":"MY Koh","year":"2012","unstructured":"Koh MY, Powis G. Passing the baton: The HIF switch. Trends Biochem Sci. 2012;37(9):364\u201372.","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"7257_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00109-010-0646-x","volume":"88","author":"G Czibik","year":"2010","unstructured":"Czibik G. Complex role of the HIF system in cardiovascular biology. J Mol Med (Berl). 2010;88(11):1101\u201311.","journal-title":"J Mol Med (Berl)"},{"issue":"4\u20135","key":"7257_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s11064-006-9268-7","volume":"32","author":"A Siddiq","year":"2007","unstructured":"Siddiq A, Aminova LR, Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: Center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res. 2007;32(4\u20135):931\u201346.","journal-title":"Neurochem Res"},{"issue":"4","key":"7257_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1139\/o02-115","volume":"80","author":"ME Lieb","year":"2002","unstructured":"Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol. 2002;80(4):421\u20136.","journal-title":"Biochem Cell Biol"},{"issue":"37","key":"7257_CR34","doi-asserted-by":"publisher","first-page":"38458","DOI":"10.1074\/jbc.M406026200","volume":"279","author":"RJ Appelhoff","year":"2004","unstructured":"Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458\u201365.","journal-title":"J Biol Chem"},{"issue":"14","key":"7257_CR35","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.113.004042","volume":"129","author":"AE Moran","year":"2014","unstructured":"Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. Circulation. 2014;129(14):1483\u201392.","journal-title":"Circulation"},{"key":"7257_CR36","doi-asserted-by":"crossref","unstructured":"Severino P, D\u2019Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction. Int J Mol Sci. 2020;21(21).","DOI":"10.3390\/ijms21218118"},{"issue":"3","key":"7257_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00395-019-0725-2","volume":"114","author":"T Schreiber","year":"2019","unstructured":"Schreiber T, Salhofer L, Quinting T, Fandrey J. Things get broken: The hypoxia-inducible factor prolyl hydroxylases in ischemic heart disease. Basic Res Cardiol. 2019;114(3):16.","journal-title":"Basic Res Cardiol"},{"issue":"13","key":"7257_CR38","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1074\/jbc.M110.186809","volume":"286","author":"M Holscher","year":"2011","unstructured":"Holscher M, Silter M, Krull S, von Ahlen M, Hesse A, Schwartz P, et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem. 2011;286(13):11185\u201394.","journal-title":"J Biol Chem"},{"issue":"3","key":"7257_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0008-6363(02)00259-6","volume":"54","author":"KG Shyu","year":"2002","unstructured":"Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, et al. Intramyocardial injection of naked DNA encoding HIF-1alpha\/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res. 2002;54(3):576\u201383.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"7257_CR40","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jacc.2005.08.045","volume":"46","author":"M Kido","year":"2005","unstructured":"Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46(11):2116\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7257_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/scrt410","volume":"5","author":"B Huang","year":"2014","unstructured":"Huang B, Qian J, Ma J, Huang Z, Shen Y, Chen X, et al. Myocardial transfection of hypoxia-inducible factor-1alpha and co-transplantation of mesenchymal stem cells enhance cardiac repair in rats with experimental myocardial infarction. Stem Cell Res Ther. 2014;5(1):22.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"7257_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.107.758516","volume":"118","author":"T Eckle","year":"2008","unstructured":"Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation. 2008;118(2):166\u201375.","journal-title":"Circulation"},{"key":"7257_CR43","doi-asserted-by":"crossref","unstructured":"Zheng J, Chen P, Zhong J, Cheng Y, Chen H, He Y, et al. HIF1alpha in myocardial ischemiareperfusion injury (Review). Mol Med Rep. 2021;23(5).","DOI":"10.3892\/mmr.2021.11991"},{"key":"7257_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2018.01.024","volume":"117","author":"S Cadenas","year":"2018","unstructured":"Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 2018;117:76\u201389.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"7257_CR45","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1253\/circj.CJ-19-1039","volume":"84","author":"H Deguchi","year":"2020","unstructured":"Deguchi H, Ikeda M, Ide T, Tadokoro T, Ikeda S, Okabe K, et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ J. 2020;84(6):1028\u201333.","journal-title":"Circ J"},{"issue":"7","key":"7257_CR46","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1089\/ars.2010.3769","volume":"15","author":"RS Adluri","year":"2011","unstructured":"Adluri RS, Thirunavukkarasu M, Dunna NR, Zhan L, Oriowo B, Takeda K, et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-\/-) attenuates ex vivo myocardial ischemia\/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice. Antioxid Redox Signal. 2011;15(7):1789\u201397.","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"7257_CR47","doi-asserted-by":"publisher","first-page":"H1571","DOI":"10.1152\/ajpheart.00291.2007","volume":"293","author":"R Natarajan","year":"2007","unstructured":"Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA 3rd. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol. 2007;293(3):H1571\u201380.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"7257_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/01.RES.0000197816.63513.27","volume":"98","author":"R Natarajan","year":"2006","unstructured":"Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler AA 3rd. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res. 2006;98(1):133\u201340.","journal-title":"Circ Res"},{"issue":"12","key":"7257_CR49","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.108.190645","volume":"104","author":"L Bautista","year":"2009","unstructured":"Bautista L, Castro MJ, Lopez-Barneo J, Castellano A. Hypoxia inducible factor-2alpha stabilization and maxi-K+ channel beta1-subunit gene repression by hypoxia in cardiac myocytes: role in preconditioning. Circ Res. 2009;104(12):1364\u201372.","journal-title":"Circ Res"},{"issue":"4","key":"7257_CR50","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1681\/ASN.2006060639","volume":"18","author":"I Kojima","year":"2007","unstructured":"Kojima I, Tanaka T, Inagi R, Kato H, Yamashita T, Sakiyama A, et al. Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol. 2007;18(4):1218\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"7257_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.WCB.0000110532.48786.46","volume":"24","author":"GS Ralph","year":"2004","unstructured":"Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, et al. Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia. J Cereb Blood Flow Metab. 2004;24(2):245\u201358.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7257_CR52","doi-asserted-by":"publisher","first-page":"864946","DOI":"10.1155\/2015\/864946","volume":"2015","author":"T Zhou","year":"2015","unstructured":"Zhou T, Chuang CC, Zuo L. Molecular Characterization of reactive oxygen species in myocardial ischemia-reperfusion injury. Biomed Res Int. 2015;2015:864946.","journal-title":"Biomed Res Int."},{"key":"7257_CR53","doi-asserted-by":"crossref","unstructured":"Zhou T, Prather ER, Garrison DE, Zuo L. Interplay between ROS and antioxidants during ischemia-reperfusion injuries in cardiac and skeletal muscle. Int J Mol Sci. 2018;19(2).","DOI":"10.3390\/ijms19020417"},{"issue":"3","key":"7257_CR54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCRESAHA.114.300507","volume":"114","author":"T Oka","year":"2014","unstructured":"Oka T, Akazawa H, Naito AT, Komuro I. Angiogenesis and cardiac hypertrophy: Maintenance of cardiac function and causative roles in heart failure. Circ Res. 2014;114(3):565\u201371.","journal-title":"Circ Res"},{"issue":"7134","key":"7257_CR55","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nature05602","volume":"446","author":"M Sano","year":"2007","unstructured":"Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444\u20138.","journal-title":"Nature"},{"issue":"37","key":"7257_CR56","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/eurheartj\/ehv294","volume":"36","author":"J Guo","year":"2015","unstructured":"Guo J, Mihic A, Wu J, Zhang Y, Singh K, Dhingra S, et al. Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2015;36(37):2530\u201340.","journal-title":"Eur Heart J"},{"issue":"1","key":"7257_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/cvr\/cvs014","volume":"94","author":"M Holscher","year":"2012","unstructured":"Holscher M, Schafer K, Krull S, Farhat K, Hesse A, Silter M, et al. Unfavourable consequences of chronic cardiac HIF-1alpha stabilization. Cardiovasc Res. 2012;94(1):77\u201386.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"7257_CR58","doi-asserted-by":"publisher","first-page":"e11693","DOI":"10.1371\/journal.pone.0011693","volume":"5","author":"R Bekeredjian","year":"2010","unstructured":"Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, et al. Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One. 2010;5(7):e11693.","journal-title":"PLoS One."},{"issue":"11","key":"7257_CR59","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1128\/MCB.01580-07","volume":"28","author":"L Lei","year":"2008","unstructured":"Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, et al. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol. 2008;28(11):3790\u2013803.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"7257_CR60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMc1600140","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.","journal-title":"N Engl J Med"},{"issue":"4","key":"7257_CR61","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"7257_CR62","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"issue":"2","key":"7257_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: A multimodality study. JACC Cardiovasc Imaging. 2021;14(2):393\u2013407.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"7257_CR64","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","volume":"9","author":"R Bessho","year":"2019","unstructured":"Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, et al. Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754.","journal-title":"Sci Rep"},{"issue":"6","key":"7257_CR65","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00125-007-0652-x","volume":"50","author":"M Lassila","year":"2007","unstructured":"Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, et al. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia. 2007;50(6):1315\u201326.","journal-title":"Diabetologia"},{"issue":"5","key":"7257_CR66","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2337\/db15-0519","volume":"65","author":"BK Nayak","year":"2016","unstructured":"Nayak BK, Shanmugasundaram K, Friedrichs WE, Cavaglierii RC, Patel M, Barnes J, et al. HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes. 2016;65(5):1387\u201397.","journal-title":"Diabetes"},{"issue":"1","key":"7257_CR67","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8(1):6791.","journal-title":"Sci Rep"},{"issue":"5","key":"7257_CR68","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","volume":"11","author":"T Cai","year":"2020","unstructured":"Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11(5):390.","journal-title":"Cell Death Dis"},{"issue":"Suppl 3","key":"7257_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2362.2005.01525.x","volume":"35","author":"KU Eckardt","year":"2005","unstructured":"Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(Suppl 3):13\u20139.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"7257_CR70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/jcmm.13319","volume":"22","author":"G Olmos","year":"2018","unstructured":"Olmos G, Munoz-Felix JM, Mora I, Muller AG, Ruiz-Torres MP, Lopez-Novoa JM, et al. Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition. J Cell Mol Med. 2018;22(1):302\u201314.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"7257_CR71","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141(8):704\u20137.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07257-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T19:06:22Z","timestamp":1668279982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07257-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7257"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07257-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"2 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors have read, approved, and contributed equally to the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}